Heart and vascular remodeling in essential hypertension and type 2 diabetes is dependent on genetic polymorphisms.
Vessel Plus 2017;1:84-90.
Anna Shalimova (Ukraine)
1) Summarize your work in one sentence.
Since the presence of controversial views on the role of gene expression and genetic polymorphisms in the development and course of diseases in different populations of patients, the aim of this study was to evaluate the influence of genetic polymorphism of the angiotensin II receptor type 1 (AGTR1) gene and peroxisome proliferator-activated receptor-γ2 (PPARγ2) on the severity of heart and vascular remodeling in essential hypertension (EH) and concomitant type 2 diabetes mellitus (DM2) in Ukrainian population of patients.
2) Summarize your findings in one sentence.
Polymorphisms of the genetic markers of the AGTR1 gene and PPARγ2 are associated with the development of comorbidity of EH and DM2: the A/C and C/C genotypes of the AGTR1 gene are characterized by significantly higher blood pressure and more pronounced cardiovascular remodeling (as compared to the A/A genotype), Pro/Pro genotype of PPARγ2 is characterized by more severe hemodynamic and metabolic disorders (as compared to the Pro/Ala and Ala/Ala genotypes).
3) Which were the more important methods you used in this work? If it is not a traditional method you can briefly explain the concept of that methodology.
An A1166C polymorphism of the AGTR1 gene and a Pro12Аla polymorphism of the PPARγ2 gene were assessed by the molecular genetic method. Other methods: biochemical blood analysis, echocardiographic evaluation of mitral diastolic blood flow and tissue Doppler spectral modes, reactive hyperemia, color Doppler mapping.
4) What did you learn from this paper, what was your take-home message?
The data obtained in this study underscore the need to consider the influence of polymorphism of genetic markers on the development and course of comorbidity of EH and DM2. The results of the medical genetic research will contribute to the development of measures for the timely prevention and treatment of EH and DM2 in patients with risk factors. The study of genetic polymorphism can be promising not only from the standpoint of diagnostics, but also from the standpoint of improving the treatment of patients with EH and comorbidity, taking into account the pharmacogenetic analysis.